TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026 at 1:30 PM PST. A live webcast will be available on the company’s Events page in the Investors & Media section at http://ir.tgtherapeutics.com/events, and a replay will be posted on TG’s website after the event.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
On the day this news was published, TGTX gained 3.16%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TGTX slipped 1.64% while peers were mixed: MRUS -7.08%, CRSP +5.55%, LEGN +3.30%, with others modestly positive. This points to stock‑specific trading rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Conference participation | Positive | -0.5% | Announcement of Evercore healthcare conference fireside chat and webcast access. |
| Nov 19 | Corporate recognition | Positive | -2.8% | Inclusion on Deloitte 2025 Technology Fast 500 list driven by BRIUMVI growth. |
| Nov 10 | Conference participation | Positive | +2.7% | Participation in TD Cowen Immunology & Inflammation Summit with investor webcast. |
| Nov 03 | Earnings results | Positive | -3.1% | Q3 2025 results with strong BRIUMVI revenue and raised full‑year guidance. |
| Oct 31 | Earnings call notice | Positive | +2.2% | Notice of Q3 2025 earnings call and business outlook webcast. |
Recent history shows several positive or recognition/participation headlines coinciding with modest negative price reactions, while some conference and earnings‑related events have seen small gains. Reactions to news have been mixed, with both alignments and divergences.
Over the last few months, TG Therapeutics reported strong fundamentals, including $161.7M in Q3 2025 revenue, driven largely by BRIUMVI, and raised 2025 revenue guidance while completing a $100M share repurchase. The company also gained visibility through multiple investor and healthcare conferences and recognition on Deloitte’s 2025 Fast 500 list. Price reactions around these events were mixed, with both positive and negative moves. Today’s J.P. Morgan Healthcare Conference participation fits into this pattern of ongoing investor outreach and commercial execution updates.
Regulatory & Risk Context
An effective Form S-3ASR filed on Aug 8, 2025 provides TG Therapeutics the ability to offer common stock, preferred stock, warrants, debt securities and units from time to time for general corporate purposes. The shelf had 0 recorded usages in the provided data, indicating no prospectus supplements yet referenced here.
Market Pulse Summary
This announcement highlights TG Therapeutics’ participation in the high‑profile J.P. Morgan Healthcare Conference on January 13, 2026, offering another platform for management to discuss BRIUMVI‑driven growth and recent financial progress. Historically, similar conference notices produced mixed price reactions. Investors tracking this name often focus on revenue trends, cash levels of $178.3M as of September 2025, the effective S-3ASR shelf from August 2025, and insider activity when evaluating future developments.
AI-generated analysis. Not financial advice.
Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PST
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Tuesday, January 13, 2026, at 1:30 PM PST.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When will TG Therapeutics (TGTX) present at the J.P. Morgan Healthcare Conference?
How can investors watch the TGTX presentation on January 13, 2026?
Will there be a replay of the TGTX J.P. Morgan presentation if I miss the live stream?
Who is presenting for TG Therapeutics (TGTX) at the January 13, 2026 session?
Where on TG Therapeutics’ website is the January 13, 2026 presentation posted?
